AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Designs cancer care systems around the body's natural upright position
Pitching Eventide Asset Management? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room